I-Freenome, inkampani yangasese ye-biotech, namhlanje ibhengeze ukuqaliswa kwe-Vallania, isifundo seklinikhi sokucokisa kunye nophuhliso oluqhubekayo lweqonga layo le-multiomics lokubona ii-cancer ezininzi. Iqonga lisebenzisa ukutsalwa kwegazi eliqhelekileyo kwaye lidibanisa zombini ithumba kunye nemiqondiso engeyiyo ithumba kunye nokufunda komatshini ukufumanisa umhlaza kwasekuqaleni, awona manqanaba anyangekayo.
I-platform ye-Freenome ibonise ukusebenza okunamandla ekufumaneni i-CRC yesigaba sokuqala, kubandakanywa idatha ebonisa uvakalelo lwe-94% kunye ne-specific ye-94% kwisigaba sokuqala (I / II) CRC. I-Freenome okwangoku iqokelela idatha yeklinikhi kubantu abangaphezu kwe-30,000 njengenxalenye ye-PREEMPT CRC, ulingo olukhulu lokubhalisa oluqinisekisa uvavanyo lwe-CRC olungenaluhlaselo lwegazi phakathi kwabantu abadala abasengozini.
Uphononongo lweVallania lusebenzisa iqonga elifanayo le-multiomics kunye nesiginitsha edibeneyo ye-multicancer ukuvavanya iimpawu ezininzi, kubandakanya imiphunga kunye nomhlaza wepancreatic, kwaye iza kwizithende zophando olunikezelwe ekwindla lokugqibela lubonisa iziphumo ezithembisayo zokufumanisa umhlaza wepancreatic. I-Freenome iphuhlisa indlela elungiselelweyo yokuhlola i-multicancer eyenza ukuba umntu abe sengozini yokubeka umngcipheko ukuze alungelelanise iindlela zokhathalelo lwezigulane kunye nokwandisa ukusetyenziswa kweklinikhi.
Uphononongo lweVallania lujolise kwiseti yokuqala yee-cancer ezineemfuno ezibalulekileyo ezingafezekanga kunye neendlela zokhathalelo ekwabelwana ngazo. Olu phononongo olulindelekileyo lubhalisa izigulane ze-5,500 kwiindawo ezingaphezu kwe-100 kulo lonke elase-United States kwaye liya kubeka iqonga lezifundo ezongezelelweyo ze-multicancer.
"Kube sisicwangciso sethu kwasekuqaleni ukwandisa amandla ethu eqonga ukubandakanya umhlaza owongezelelweyo ngaphaya kweCRC," utshilo uMike Nolan, igosa elilawulayo leFreenome. “Sigxile ekuguquleni imeko yokhathalelo lomhlaza ngokwenza ukuba kubonwe kwangethuba kunye nokungenelela. Uphononongo lwaseVallania linyathelo eliphambili lokufikelela olo sukelo.”
Izifundo zeklinikhi zikaFreenome zithiywe ngabathandekayo babasebenzi abaye balwa nomhlaza. Olu phononongo luwonga umama wesazinzulu saseFreenome owalwa nomhlaza wepancreatic.
INTO ONOKUYITHATHA KWELI NQAKU:
- The Vallania Study uses the same multiomics platform with its embedded multicancer signatures to test for several indications, including lung and pancreatic cancers, and comes on the heels of research presented last fall showing promising results in detecting pancreatic cancer.
- Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study for the refinement and further development of its multiomics platform to detect multiple cancers.
- Freenome’s platform has shown strong performance in detecting early stage CRC, including data showing a sensitivity of 94% and a specificity of 94% for early-stage (I/II) CRC.
